Calcitonin gene-related peptide modulates interleukin-13 in circulating cutaneous lymphocyte-associated antigen-positive T cells in patients with atopic dermatitis
Calcitonin gene-related peptide modulates interleukin-13 in circulating cutaneous lymphocyte-associated antigen-positive T cells in patients with atopic dermatitis
复制标题
DOI:
10.1111/j.1365-2133.2009.09318.x
复制
发表时间:
2009-09-01
影响因子:
10.3
通讯作者:
Santamaria-Babi, L. F.
中科院分区:
文献类型:
--
作者:
Antunez, C.;Torres, M. J.;Santamaria-Babi, L. F.
Background Neuropeptides (NPs) may play an important role in the pathogenesis of atopic dermatitis (AD) by regulating immune responses and contributing to the cross-talk between the immune and nervous systems.Objectives To assess the ability of NPs to influence interleukin (IL)-13 and interferon (IFN)-gamma production and the expression of the activation marker HLA-DR in skin memory T cells [cutaneous lymphocyte-associated antigen (CLA)+ T cells] from patients with AD with severe, chronic lesions and intense pruritus, and from nonatopic controls.Methods Cells were cultured in the presence and absence of different NPs, calcitonin gene-related peptide (CGRP), somatostatin (SOM) and substance P (SP). IL-13 and IFN-gamma production and HLA-DR expression were measured in both CLA+ and CLA) T-cell subsets by flow cytometry.Results CGRP increased IL-13 production in peripheral blood mononuclear cells from patients with AD (P < 0 05), with no changes detected in the presence of SOM or SP. These patients with AD had a lower expression of CGRP receptor compared with controls (P < 0 05). Memory T cells incubated with CGRP also showed an increase in IL-13 (P < 0 05) and HLA-DR (P < 0 05) in CLA+ T cells from patients with AD compared with controls, but not in CLA) T cells. Patients with a higher production of IL-13 were those with higher total IgE and percentage of skin area involved. Furthermore, the IL-13/IFN-gamma ratio was increased in patients with AD after cells were cultured with CGRP (P < 0 05).Conclusions Our results suggest an immunomodulatory role of CGRP towards a Th2 pattern in CLA+ T cells, which may contribute to exacerbating clinical symptoms in patients with AD.